Sebastian P Haen1,2, Michael Schumm3, Christoph Faul4, Lothar Kanz4, Wolfgang A Bethge4, Wichard Vogel4. 1. Abteilung II für Onkologie, Hämatologie, Immunologie, Rheumatologie und Pulmologie, Medizinische Universitätsklinik Tübingen, Otfried Müller Str. 10, 72076, Tübingen, Germany. sebastian.haen@med.uni-tuebingen.de. 2. Abteilung Immunologie, Interfakultäres Institut für Zellbiologie, Auf der Morgenstelle 15, 72076, Tübingen, Germany. sebastian.haen@med.uni-tuebingen.de. 3. Klinik für Kinder- und Jugendmedizin, Hoppe Seyler Str. 1, 72076, Tübingen, Germany. 4. Abteilung II für Onkologie, Hämatologie, Immunologie, Rheumatologie und Pulmologie, Medizinische Universitätsklinik Tübingen, Otfried Müller Str. 10, 72076, Tübingen, Germany.
Abstract
PURPOSE: Insufficient production of leukocytes, thrombocytes and erythrocytes after allogeneic peripheral blood stem cell transplantation (PBSCT) represents a life-threatening complication. METHODS: In 20 adult patients with poor graft function (PGF defined as transfusion-dependent platelet counts <20,000/µl, or leukocytes <1500/µl, or transfusion-dependent anemia) and variable causes of PGF after allogeneic PBSCT, immunomagnetically selected CD34(+) stem cell boosts (SCB) from matched unrelated (n = 8), mismatched unrelated (n = 11) or haploidentical (n = 1) donors were applied without prior conditioning. RESULTS: Patients received a median of 4.6 × 10(6) CD34(+) cells per kilogram bodyweight (1.9-9.1 × 10(6)) and low T cell numbers (median 0.2 × 10(4), range 0.04-0.6 × 10(4)). All patients showed responses in at least one hematopoietic lineage. Engraftment for platelets, leukocytes and hemoglobin was 88, 88 and 100 % after a median of 14, 13 and 18 days, respectively. With regard to the complete cohort, 90 % (n = 18) showed an increase in platelets (median 76,500/µl, range -7000 to 223,000/µl), 95 % (n = 19) had an increase in leukocytes (median 3110/µl, range 150-13,740/µl) and 90 % (n = 18) improved with regard to hemoglobin (median 1.9 g/dl, range -0.9 to 5.1 g/dl). Due to effective T cell depletion, only one patient developed graft versus host disease (GvHD, grade III) after SCB. Patients were followed for a median of 7.5 months (1-74 months) with 11 patients being alive and disease free with normalized peripheral blood counts at the end of follow-up. CONCLUSIONS: CD34(+)-selected SCB are safe and effective and can durably improve PGF even in patients receiving grafts from unrelated matched or mismatched donors with low incidence of GvHD.
PURPOSE: Insufficient production of leukocytes, thrombocytes and erythrocytes after allogeneic peripheral blood stem cell transplantation (PBSCT) represents a life-threatening complication. METHODS: In 20 adult patients with poor graft function (PGF defined as transfusion-dependent platelet counts <20,000/µl, or leukocytes <1500/µl, or transfusion-dependent anemia) and variable causes of PGF after allogeneic PBSCT, immunomagnetically selected CD34(+) stem cell boosts (SCB) from matched unrelated (n = 8), mismatched unrelated (n = 11) or haploidentical (n = 1) donors were applied without prior conditioning. RESULTS:Patients received a median of 4.6 × 10(6) CD34(+) cells per kilogram bodyweight (1.9-9.1 × 10(6)) and low T cell numbers (median 0.2 × 10(4), range 0.04-0.6 × 10(4)). All patients showed responses in at least one hematopoietic lineage. Engraftment for platelets, leukocytes and hemoglobin was 88, 88 and 100 % after a median of 14, 13 and 18 days, respectively. With regard to the complete cohort, 90 % (n = 18) showed an increase in platelets (median 76,500/µl, range -7000 to 223,000/µl), 95 % (n = 19) had an increase in leukocytes (median 3110/µl, range 150-13,740/µl) and 90 % (n = 18) improved with regard to hemoglobin (median 1.9 g/dl, range -0.9 to 5.1 g/dl). Due to effective T cell depletion, only one patient developed graft versus host disease (GvHD, grade III) after SCB. Patients were followed for a median of 7.5 months (1-74 months) with 11 patients being alive and disease free with normalized peripheral blood counts at the end of follow-up. CONCLUSIONS:CD34(+)-selected SCB are safe and effective and can durably improve PGF even in patients receiving grafts from unrelated matched or mismatched donors with low incidence of GvHD.
Entities:
Keywords:
Allogeneic hematopoietic cell transplantation; CD34+-selected stem cell boost; Graft versus host disease; Poor graft function
Authors: P Guardiola; M Kuentz; F Garban; D Blaise; J Reiffers; M Attal; A Buzyn; B Lioure; P Bordigoni; N Fegueux; M L Tanguy; J P Vernant; E Gluckman; G Socié Journal: Br J Haematol Date: 2000-10 Impact factor: 6.998
Authors: M Schumm; P Lang; G Taylor; S Kuçi; T Klingebiel; H J Bühring; A Geiselhart; D Niethammer; R Handgretinger Journal: J Hematother Date: 1999-04
Authors: Aa Oyekunle; U Koehl; H Schieder; F Ayuk; H Renges; N Fehse; T Zabelina; B Fehse; T Klingebiel; A Sputtek; Ar Zander; N Kröger Journal: Cytotherapy Date: 2006 Impact factor: 5.414
Authors: Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Gabriela Rondón; Rima M Saliba; Issa Khouri; Sergio Giralt; Kawah Chan; Elias Jabbour; John McMannis; Richard Champlin; Elizabeth Shpall Journal: Biol Blood Marrow Transplant Date: 2008-08 Impact factor: 5.742
Authors: M Remberger; O Ringdén; P Ljungman; H Hägglund; J Winiarski; B Lönnqvist; J Aschan Journal: Bone Marrow Transplant Date: 1998-07 Impact factor: 5.483
Authors: Sebastian P Haen; Vicky Eyb; Nora Mirza; Aline Naumann; Andreas Peter; Markus W Löffler; Christoph Faul; Wichard Vogel; Wolfgang A Bethge; Hans-Georg Rammensee; Lothar Kanz; Martin Heni Journal: J Cancer Res Clin Oncol Date: 2017-02-16 Impact factor: 4.553
Authors: Tami John; Jolan E Walter; Catherina Schuetz; Karin Chen; Roshini S Abraham; Carmem Bonfim; Thomas G Boyce; Avni Y Joshi; Elizabeth Kang; Beatriz Tavares Costa Carvalho; Arash Mahajerin; Diane Nugent; Geetha Puthenveetil; Amit Soni; Helen Su; Morton J Cowan; Luigi Notarangelo; David Buchbinder Journal: J Clin Immunol Date: 2016-08-18 Impact factor: 8.317
Authors: Armin Ghobadi; Mark A Fiala; Giridharan Ramsingh; Feng Gao; Camille N Abboud; Keith Stockerl-Goldstein; Geoffrey L Uy; Brenda J Grossman; Peter Westervelt; John F DiPersio Journal: Biol Blood Marrow Transplant Date: 2017-03-18 Impact factor: 5.742
Authors: Emily C Liang; Lori S Muffly; Parveen Shiraz; Judith A Shizuru; Laura Johnston; Sally Arai; Matthew J Frank; Wen-Kai Weng; Robert Lowsky; Andrew Rezvani; Everett H Meyer; Robert Negrin; David B Miklos; Surbhi Sidana Journal: Transplant Cell Ther Date: 2021-02-25
Authors: Haneen Shalabi; Juliane Gust; Agne Taraseviciute; Pamela L Wolters; Allison B Leahy; Carlos Sandi; Theodore W Laetsch; Lori Wiener; Rebecca A Gardner; Veronique Nussenblatt; Joshua A Hill; Kevin J Curran; Timothy S Olson; Colleen Annesley; Hao-Wei Wang; Javed Khan; Marcelo C Pasquini; Christine N Duncan; Stephan A Grupp; Michael A Pulsipher; Nirali N Shah Journal: Nat Rev Clin Oncol Date: 2021-01-25 Impact factor: 66.675